Breaking News, Collaborations & Alliances

Sorrento, Conkwest to Develop Next-Gen CAR-TNK Immunotherapies

Will focus on treatment of hematological malignancies and solid tumors

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sorrento Therapeutics, Inc. and Conkwest, Inc. have entered into a definitive agreement to jointly develop next generation CAR-TNK immunotherapies for the treatment of cancer. The CAR-TNK technology platform combines Conkwest’s Neukoplast cell line with Sorrento’s G-MAB fully human antibody technology and CAR designs to enhance potency and targeting of Neukoplast. The companies will focus on accelerating the development of CAR-TNKs for the treatment of hematological malignancies as ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters